Capecitabine in combination with docetaxel can be a therapeutic alternative when ALL the following criteria are met: 1.Patients with locally advanced or metastatic breast cancer. 2.Patients failed or are not elegible for antracycline containing regimens. It must be taken into account that, up until now, the main evidence about capecitabine comes from one randomized clinical trial which showed a three-month survival improvement. As a single agent therapy, the evidence is of less quality and could be considered as a therapeutic alternative for patients who meet ALL these criteria:
Patients with locally advanced or metastatic breast cancer and one of the following: 3.Patients who have not already received capecitabine as combined therapy and have failed antracycline or taxane regimens; or 4.Patients for whom another antracycline treatment is contraindicated.